Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run into some unforseen safety issues with a hep-C candidate called INX-189. Gilead’s…
Surging growth of its Cymbalta depression treatment helped Eli Lilly & Co. (NYSE: LLY) beat Wall St.’s earnings expectations. But generic rivals to Plavix, other drugs hurt Bristol-Myers Squibb Co. (NYSE: BMY)…
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from…
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported adjusted diluted EPS of…
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block.…
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech…
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is effectively…
As of late last week we had many potentially imminent buyouts that could have hit the market. When we were just finishing the report draft on Friday is when the Amylin Pharmaceuticals,…
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. Bristol-Myers…
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around…
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set…
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the biggest public merger rumors out there. At least that is the belief of Wall…
Markets opened a few ticks lower this morning after a poor report on new claims for unemployment benefits in the US (our coverage here). The report that pending home sales jumped 4.1%…
Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company. With another small-cap to mid-cap biotech and emerging pharma company…
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from Bristol-Meyers…
